Overview

A Phase I Study of GZR18 Injection in Healthy Subjects

Status:
COMPLETED
Trial end date:
2022-10-20
Target enrollment:
Participant gender:
Summary
This trial is conducted in China. The aim of the trial is to evaluate the safety and tolerability of GZR18 injection in healthy subjects following single dose and once-weekly dose for 2 consecutive weeks until reaching the target dose.
Phase:
PHASE1
Details
Lead Sponsor:
Gan and Lee Pharmaceuticals, USA